Related Experiment Video
Updated: Aug 5, 2026
Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo
Published on: July 25, 2025
Pyra-Metho-Carnil Suppresses CD73-associated Macrophage Infiltration in KRAS-mutant Colorectal Cancer
Takanori Kitaguchi1,2,3, Seimon Abe1,2, Taichi Matsumoto1,2
1Department of Cell Biology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
Background/Aim:
We previously reported that Pyra-Metho-Carnil (PMC) suppresses macrophage differentiation in co-culture with mutant (mt) Kirsten rat sarcoma (KRAS) tumors. In this study, we used integrative proteomics and identified a KRAS-regulated membrane and exosomal protein, 5'-nucleotidase ecto (NT5E)/CD73, as a key candidate linking KRAS signaling to macrophage-associated tumor immune microenvironment (TIME) remodeling. We investigated whether PMC modulates CD73-associated pathways during macrophage differentiation.
Materials And Methods:
THP-1 cells were differentiated with phorbol 12-myristate 13-acetate (PMA) and treated with PMC or a CD73 inhibitor (CD73i). Three-dimensional (3D) co-culture assays were performed using HKe3 wild-type (wt) KRAS or HKe3 mt KRAS spheroids. Macrophage infiltration into spheroids was evaluated by live-cell imaging and immunohistochemistry (IHC) of co-cultured spheroid sections. Using clinical colorectal cancer (CRC) specimens, the co-localization of CD73+ tumor cells and CD68+ macrophages was examined.
Results:
IHC of co-cultured spheroid sections revealed that PMC treatment reduced THP-1-derived macrophage infiltration into mt-KRAS spheroids. Notably, while CD73i reproduced only the effect on macrophage infiltration, PMC demonstrated a more comprehensive antitumor effect by suppressing both CD73-mediated infiltration and direct tumor cell proliferation. Analysis of clinical mt-KRAS CRC tissues revealed significant clustering of CD73+ tumor cells and CD68+ macrophages specifically at the invasive fronts. In contrast, such infiltration was minimal in non-invasive regions or wt-KRAS tissues.
Conclusion:
These findings suggest that PMC suppresses macrophage infiltration and promotes TIME reprogramming through mechanisms associated with CD73 regulation. Therefore, by targeting tumor growth and immune evasion, PMC offers superior therapeutic value over conventional CD73i in mt-KRAS CRC, where CD73 expression correlates with clinical macrophage clustering.
Insights
Pyra-Metho-Carnil (PMC) effectively targets mutant KRAS colorectal cancer by inhibiting CD73-mediated macrophage infiltration and tumor cell proliferation. This dual action offers superior therapeutic value compared to CD73 inhibitors alone.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Pyra-Metho-Carnil (PMC) previously showed suppression of macrophage differentiation with mutant (mt) Kirsten rat sarcoma (KRAS) tumors.
- Integrative proteomics identified 5'-nucleotidase ecto (NT5E)/CD73 as a KRAS-regulated protein linking KRAS signaling to tumor immune microenvironment (TIME) remodeling.
Purpose of the Study:
- To investigate if PMC modulates CD73-associated pathways during macrophage differentiation.
- To explore the therapeutic potential of PMC in mt-KRAS colorectal cancer (CRC).
Main Methods:
- THP-1 cells were differentiated and treated with PMC or a CD73 inhibitor (CD73i).
- Three-dimensional (3D) co-culture assays used wild-type (wt) KRAS or mt KRAS spheroids.
- Macrophage infiltration was assessed via live-cell imaging and immunohistochemistry (IHC).
- Co-localization of CD73+ tumor cells and CD68+ macrophages was examined in clinical CRC specimens.
Main Results:
- PMC reduced macrophage infiltration into mt-KRAS spheroids, an effect also seen with CD73i.
- PMC demonstrated broader antitumor effects by suppressing both CD73-mediated infiltration and tumor cell proliferation.
- Clinical mt-KRAS CRC tissues showed significant clustering of CD73+ tumor cells and CD68+ macrophages at invasive fronts.
Conclusions:
- PMC suppresses macrophage infiltration and reprograms TIME via CD73 regulation.
- PMC exhibits superior therapeutic value over CD73i in mt-KRAS CRC by targeting tumor growth and immune evasion.
- Clinical CD73 expression correlates with macrophage clustering in CRC, supporting PMC's therapeutic relevance.
